Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Bristol hopes to Tyk the psoriasis box
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
AAD 2020 – Leo’s eczema wildcard proves tame
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
UCB’s growth driver squares up against the competition
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
